Sage Therapeutics (SAGE)
(Real Time Quote from BATS)
$12.07 USD
+0.36 (3.07%)
Updated May 16, 2024 12:42 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 41 - 60 ( 157 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zuranolone Zipping Along As FDA Accepts Filing, Grants Priority Review
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Rolling NDA Submission For Zuranolone is Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zuranolone Filing Nears Finish Line; Reiterate Neutral; Price Target Down to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
With Zuranolone On Track, 2023 Will Be Regulatory Focused
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Regulatory Shift for Zuranolone - We Think In A Good Way
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Does Skylark''s Success Complete the Zuranolone Puzzle? Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology - Let''s Enjoy A Positive Update For A Moment - Zuranolone SKYLARK Hits
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Uneventful 4Q as Zuranolone NDA Submission Gets Rolling
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
As Zuranolone Rolls Ahead, Looking Forward to SKYLARK Mid-2022
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Quiet 4Q21 Call Ahead of Zuranolone Rolling NDA This Year; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
CORAL Hits Primary Endpoint But Data Raises Many More Questions Than It Answers; Reit Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
CORAL Hits Primary Endpoint; Debate Likely To Persist
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L